Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial
Orchestra BioMed Holdings, Inc. - Ordinary Shares (OBIO)
Company Research
Source: GlobeNewswire
Orchestra BioMed’s Virtue® Sirolimus AngioInfusionTM Balloon (“Virtue SAB”) is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release sirolimus (“SirolimusEFRTM”)The Virtue Trial is the first U.S. investigational device exemption (“IDE”) head-to-head randomized coronary pivotal trial evaluating a sirolimus-eluting balloon versus a commercially available paclitaxel-coated balloon (AGENT™) Coronary in-stent restenosis (“ISR”), the clinical focus of the Virtue Trial, is a difficult-to-treat and serious complication of coronary stenting that increases the risk of life-threatening heart problems, affecting an estimated 100,000 patients in the U.S. annuallyVirtue SAB has FDA Breakthrough Device Designation for the treatment of coronary ISR, as well as for coronary small vessel disease and below-the-knee peripheral artery disease NEW HOPE, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO
Show less
Read more
Impact Snapshot
Event Time:
OBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OBIO alerts
High impacting Orchestra BioMed Holdings, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
OBIO
News
- Analyst Confidence in Orchestra BioMed Holdings (OBIO) High Amid Key Clinical and Strategic Advancements [Yahoo! Finance]Yahoo! Finance
- Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Orchestra BioMed (NASDAQ:OBIO) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.MarketBeat
- Orchestra BioMed (NASDAQ:OBIO) had its price target lowered by analysts at Barclays PLC from $12.00 to $11.00. They now have an "overweight" rating on the stock.MarketBeat
OBIO
Sec Filings
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- 11/21/25 - Form 424B3
- OBIO's page on the SEC website